Catapult Therapeutics receives FDA Clearance of Investigational New Drug (IND) Application for CAP-100, an innovative first-in-class humanized anti-CCR7 antibody 8 February 2021
Pepscan grants Bicycle Therapeutics a global CLIPS Technology license for product candidates BT1718 and THR- 149 20 November 2020
Glycostem initiates phase I/IIa trial of oNKord® in patients with Acute Myeloid Leukemia 20 November 2020
Clinical benefit from immune checkpoint inhibition in advanced melanoma and NSCLC can be predicted by tyrosine kinase activity profiling 21 September 2020
“Pepscan has been the reliable expert partner for us with the right capacities to start our clinical journey” 3 July 2020
Zelluna Immunotherapy and Glycostem Therapeutics announce partnership to develop allogeneic TCR-NK therapies 19 November 2019
